Immunohistochemistry Market Size, Share & Trends Analysis Report By Product (Kits, Antibodies), By Application (Diagnostics, Drug Testing), By End-use (Research Institutes, Hospitals & Diagnostic Labs), And Segment Forecasts, 2022 - 2030

Report Overview

The global immunohistochemistry market size was valued at USD 1.89 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 8.4% from 2022 to 2030. Increasing implementation of automation and machine learning in IHC, coupled with the introduction of technologically advanced Immunohistochemistry (IHC)  solutions, is expected to significantly drive the market over the forecast period. Advancements in IHC protocols have boosted its demand to a significant level in disease diagnosis. In addition, the rise in product approvals and the launch of technologically advanced IHC systems for disease diagnosis are further propelling the market growth.

For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Companies continue to launch novel products to strengthen their market position, which leads to revenue generation. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit to detect and profile biomarkers and cell populations in tissue-based research. This kit can be utilized in combination with other detection kits, expanding the multiplexing capacity of in situ hybridization andIHC. The immunohistochemistry technology is limited to single parametric evaluations of a sample.

Newer techniques, such as multiplexed IHC, however, allow multiparametric and detailed analysis from a single tissue segment by utilizing advanced methods of mass spectrometric detection. Multiplexed IHC helps address the technical challenges posed by the labeled fluorescence detection-based method, thereby spurring the market revenue.The growing elderly population in both developed and emerging nations would favorably impact the market. The frequency of age-related disorders is expected to rise dramatically as the global geriatric population grows significantly. RT-PCR, IHC, and an electron microscope were used to detect the virus, indicating that the effect of SARS-CoV-2 is not limited to the lungs.

Product Insights

The antibodies segment dominated the market in 2021 and accounted for the largest share of more than 40.5% of the global revenue owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products, such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate. The antibodies are applied across a wide range of applications, such as pathology, neuropathology, and hematopathology. The kits segment is anticipated to expand at the fastest CAGR during the forecast period.

The use of kits reduces a lot of effort during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample. The compact nature and ease of use offered by the products under this segment are expected to drive the segment. IHC kits are commonly utilized in academic institutions and research laboratories that require these products in small quantities for carrying out research. Thus, a rising number of research programs that involve the use of IHC assays are contributing to the segment growth.

Application Insights

On the basis of applications, the global market has been further bifurcated into diagnostics and drug testing segments. The diagnostics application segment accounted for the largest revenue share of more than 69. 00% in 2021 and is anticipated to maintain its lead over the forecast period. Immunohistochemistry tests are widely used for the diagnosis of a wide range of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, diabetes mellitus, autoimmune diseases, and nephrological diseases.Furthermore, the growing prevalence of chronic diseases is anticipated to drive the diagnostics segment.

According to the data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With a rise in the number of cancer cases, the need for IHC techniques for rapid and efficient diagnosis is high.Thus, the rising R&D activities by pharmaceutical companies for the research and development of innovative drugs are anticipated to increase the demand for IHC solutions and drive the segment. For instance, in July 2021, NHS England declared a novel innovative medicine fund to accelerate the research & development of new drugs.

End-use Insights

On the basis of end-uses, the global market has been further sub-segmented into hospitals & diagnostic laboratories, research institutes, and others. In 2021, the hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of more than 70.5% of the overall revenue. This growth was attributed to the high volume of IHC tests carried out in hospital settings. Furthermore, with the constant changes in the healthcare industry, the need for hospitals with advanced facilities has also increased. This, in turn, is also expected to augment the revenue flow in this segment.

Research institutes are expected to register a lucrative CAGR during the forecast period. This is because the technique offers several advantages over conventionally used staining techniques in pharmaceutical R&D. For instance, a human-specific IHC-approved VISTA rabbit monoclonal antibody, manufactured by Cell Signaling Technology, is available for biomedical research use.The growth can be also attributed to the wide adoption of IHC techniques in drug testing by research institutes. The technique allows the evaluation of biomarker distribution and localization and different protein expressions in varied biological tissue sections, which is conducted in research settings. Research institutes play a significant role by applying IHC techniques in drug development for the evaluation of drug efficacy tests.

Regional Insights

On the basis of regions, the global market has been further sub-categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2021 and accounted for the largest share of more than 38.5% of the global revenue. Key factors contributing to the regional market growth include the presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.

For instance, in June 2021, PathAI, a U.S.-based developer of AI-powered technology for pathological applications, showcased a machine learning-based quality control tool, designed for HER2 testing in breast cancer, at the American society of clinical oncology virtual scientific program 2021. Asia Pacific is expected to witness the fastest CAGR during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets. Furthermore, a large patient pool in countries, such as India and China, provides a large number of clinical subjects to carry out IHC R&D assays, resulting in revenue growth.

Key Companies & Market Share Insights

With the rising demand for IHC assays in cancer diagnostics, the key players are undertaking various strategic initiatives in the field of IHC, including new product launches, mergers & acquisitions, and regional expansion, to meet the market needs.For instance, in January 2021, Biocare medical LLC launched the ONCORE Pro, a fully automated in vitro diagnostic benchtop system for In-situ Hybridization (ISH) and IHC applications. In January 2021, Abcam and Shuwen Biotech (Shuwen) entered into a strategic alliance for developing and commercializing Companion Diagnostics (CDx). Under the agreement, Abcam is providing recombinant rabbit monoclonal antibodies to Shuwen Biotech for further immunohistochemical verification. Some prominent players in the global immunohistochemistry market include:

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd.

• Merck KGaA

• Danaher Corporation

• Perkinelmer, Inc.

• Bio-Rad Laboratories, Inc.

• Cell Signaling Technology, Inc.

• Bio SB

• Agilent Technologies, Inc.

• Abcam plc. 

Immunohistochemistry Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global immunohistochemistry market report on the basis of product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Antibodies

    • Primary Antibodies

    • Secondary Antibodies

  • Equipment

    • Slide Staining System

    • Tissue Microarrays

    • Tissue Processing Systems

    • Slide Scanners

    • Others

  •  Reagents

    • Histological stains

    • Blocking Sera and Reagents

    • Chromogenic Substrates

    • Fixation Reagents

    • Stabilizers

    • Organic Solvents

    • Proteolytic Enzymes

    • Diluents

  • Kits

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnostics

    • Cancer

    • Infectious Diseases

    • Cardiovascular Diseases

    • Autoimmune Diseases

    • Diabetes Mellitus

    • Nephrological Diseases

  • Drug Testing

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Diagnostic Laboratories

  • Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE